Loading, Please Wait...
DAVIS, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Marrone Bio Innovations Inc. (MBI) (NASDAQ: MBII), a leading global provider of bio-based pest management and plant health products, today announced that Zack Moye has joined as Southeastern U.S. Territory Sales Manager.
In the Southeastern U.S., agricultural production is widespread and diverse including such crops as corn, soybeans, cotton, peanuts, tomatoes, peppers, strawberries, citrus and cucurbits, making it a critical area to provide the latest information around new advances in biological integrated programs for nematode, disease and pest management. Partnerships between commodity groups, extension offices and manufacturers are critical in providing farmers with the most reliable and useful information possible.
Moye brings more than 10 years of sales and customer management experience in the Southeastern U.S., having developed successful business plans in the medical and agriculture and turf biotechnology fields. Over the years, he has held a number of roles of increasing responsibility around microbial genetics, crop protection, horticulture, soil and plant health. He has fostered longstanding relationships centered around his commitment to the community and addressing challenges that are unique to the region due to weather and climate, soil, and irrigation variability.
In his new role, Moye will focus on driving increased revenue growth in the Southeast U.S. territory by building and overseeing full sales cycle activities. He will be responsible for developing and implementing a territory plan and expanding the company’s customer base and presence of MBI products in Texas, Georgia, Kentucky and Tennessee. He will also work closely with marketing, field development and other internal teams to ensure the alignment of strategic sales goals throughout the organization.
Most recently, Moye was a pharmaceutical sales specialist for JDS Therapeutics, where he developed several strategic sales plans that resulted in notable success. He achieved the highest sales growth for a single territory across the nation, within less than one year. Previously, he worked at Wraser Pharmaceuticals in a similar role, where he helped build and develop product and customer lifecycle plans, which strengthened organizational infrastructure and drove achievement of key initiatives. Before Wraser Pharmaceuticals, he had multiple sales and management positions over the course of seven years, including at BASF and Monsanto. Moye holds a B.S. in horticulture science from the University of Georgia.
“Mr. Moye brings a wealth of knowledge to MBI around biotechnology and field development. His experience in the medical side of biotechnology as well as his number of years in agriculture bring a unique set of skills,” said Barner Jones, MBI’s Director of Sales and Account Management. “The fact that Mr. Moye has managed a myriad of sales and marketing campaigns in both worlds, all the while building relationships between the two, demonstrates his ability to stay flexible and resilient in some of the most challenging spaces. I am looking forward to having him as part of the team and seeing this territory meet customers’ needs in the Southeast."
About Marrone Bio Innovations
Marrone Bio Innovations Inc. (NASDAQ: MBII) strives to lead the movement to a more sustainable world through the discovery, development and sale of innovative biological products for crop protection, plant health and waterway systems treatment that support a better tomorrow for farmers, turf managers and consumers around the globe. MBI has screened over 18,000 microorganisms and 350 plant extracts, leveraging its in-depth knowledge of plant and soil microbiomes enhanced by advanced molecular technologies to rapidly develop seven effective and environmentally responsible pest management products to help customers operate more sustainably while uniquely improving plant health and increasing crop yields. Supported by a robust portfolio of over 400 issued and pending patents around its superior natural product chemistry, MBI’s currently available commercial products are Regalia®, Stargus®, Grandevo®, Venerate®, Majestene®, Haven® and Amplitude™, Zelto® and Zequanox®.
Marrone Bio Innovations Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date. Examples of such statements include the potential of the MBI’s products and market projections. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company’s control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including weather, regulatory and other factors affecting demand for the MBI’s products, any difficulty in marketing MBI’s products in its target markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of current information, future events or otherwise.
MBI Investor Relations:
Greg Falesnik, Managing Director
MZ Group – MZ North America